Skip to content

LSD for anxiety: all studies

Page 7 of 10: studies 61 to 70 of 96, newest first. Back to the LSD for anxiety overview

Research

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

European Neuropsychopharmacology October 17, 2020 Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder et al. 121 citations

There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to...

DOI: 10.1016/j.euroneuro.2020.10.002 (opens in new tab) Anxiety Mood Vigilance psychology Cognition +7

After more than sixty years we are still unclear whether LSD has a place in clinical psychiatry

Research in Psychotherapy Psychopathology Process and Outcome October 1, 2020 Arthur Saniotis 1 citation

Dear Editor, The use of the psychedelic Lysergic Acid Diethylamide (LSD) has again provoked scientific debate over its efficacy and safety. In the 1950s-1960s LSD was used in psychotherapy for treating depression, anxiety related to terminal cancer, addiction, and pain. (...)

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Journal of Psychopharmacology August 25, 2020 Johannes G. Ramaekers, Nadia R. P. W. Hutten, Natasha L. Mason et al. 95 citations

Background: Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim: The present...

Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression

ACS Chemical Neuroscience March 5, 2020 Meghan Hibicke, Alexus N. Landry, Hannah M. Kramer et al. 211 citations

Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of...

Psychedelics and dissociative substances

March 1, 2020 Adam Winstock, James W. Rucker 29 citations

Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Frontiers in Psychiatry January 21, 2020 Juan José Fuentes, Francina Fonseca, Matilde Elices et al. 176 citations

Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a...

DOI: 10.3389/fpsyt.2019.00943 (opens in new tab) Anxiety Addiction Randomized controlled trial Clinical trial +5

LSD Overdoses: Three Case Reports

Journal of Studies on Alcohol and Drugs 2020 Mark Haden, Birgitta Woods 31 citations

OBJECTIVE: In academic settings around the world, there is a resurgence of interest in using psychedelic substances for the treatment of addictions, posttraumatic stress disorder, depression, anxiety, and other diagnoses. This case series describes the medical consequences of accidental overdoses in three individuals. METHOD: Case series of information were gathered from interviews, health...

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer

BMC Psychiatry October 28, 2019 Rafael G. Dos Santos, José Carlos Bouso, Jaime E. C. Hallak 17 citations

In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics...

Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Swiss Medical Weekly September 30, 2019 Felix Mller, Stefan Borgwardt 10 citations

Lysergic acid diethylamide (LSD) is a potent hallucinogenic substance that was extensively investigated by psychiatrists during the 1950s and 1960s. Researchers were interested in the unique effects induced by this substance, some of which resemble symptoms seen in schizophrenia. Moreover, during that period LSD was studied and used for the treatment of several mental disorders such as...

Faces of HPPD: Hallucinogen Persisting Perception Disorder Patient Survey Results and a Descriptive Analysis of Patient Demographics, Medical Background, Drug Use History, Symptoms, and Treatments

Addictive Disorders & Their Treatment June 10, 2019 Doreen M. Lewis 2 citations

Objective: The purpose of the present study was to obtain patient information across a wide geography about medical history, drug use, symptoms, and treatments of individuals diagnosed with hallucinogen persisting perception disorder (HPPD). Methods: The study was an internet survey that yielded 26 HPPD patients from North America (81%), Europe (12%), and South America (almost 8%),...